Modality
ERT
MOA
TROP-2 ADC
Target
C5
Pathway
mTOR
Urothelial CaDMDPsoriasis
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
Feb 2023
→ Mar 2031
Phase 1Current
NCT05815056
29 pts·DMD
2023-02→2031-03·Recruiting
NCT08852399
849 pts·DMD
2025-05→TBD·Not yet recruiting
878 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-285.0y awayPh2 Data· DMD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2031-03-28 · 5.0y away
DMD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05815056 | Phase 1/2 | DMD | Recruiting | 29 | 6MWD |
| NCT08852399 | Phase 1/2 | DMD | Not yet recr... | 849 | HbA1c |
Competitors (10)